Veterinary Vaccines Market Value Analysis:
Veterinary Vaccines Market has seen significant growth over the past few years, due to fear of imminent epidemics that have led to substantial losses, particularly in poultry segment. The Animal Vaccines Market is poised to reach USD 8.46 Billion by 2023 from USD 6.47 Billion in 2018, at a CAGR of 5.5% from 2018 to 2023.
Veterinary Vaccines Market Drivers and Restraints Overview:
Veterinary Vaccine market has shown significant growth in recent years which can be attributed to increasing husbandry practices and better management of farms. This marks the estimation of further growth in the market due to advancement in biotechnological research. The global veterinary vaccines market has undergone considerable progress during the past few years with the growing usage of continuous cell lines as a substrate and embracing of the fermenter technology for antigen production. These vaccines are produced for administration by parenteral or oral routes depending on the vaccine characteristics.
Growing prevalence of animal diseases, rising incidences of zoonotic diseases in humans; increasing investments by leading players, various government agencies, and animal associations; continuous innovations, increasing awareness against the use of antimicrobials is driving the vaccine producers to invest significantly into the development of new products. However, rising maintenance costs for the storage of vaccines, increasing adoption of a vegetarian diet in major economies owing to the increased risk of obesity and other chronic diseases are key restraints of this market.
Veterinary Vaccines Market Segment:
The market has been categorized as livestock and companion vaccines. The livestock vaccines segment has been further segmented into five categories namely, bovine, porcine, ovine, poultry and equine. The companion animal vaccines segment has also been further categorized into feline and canine vaccines. In addition, based on production technologies the market is segmented as live attenuated vaccines, inactivated vaccines, recombinant vaccines, toxoid vaccines, subunit vaccines, DNA vaccines and conjugate vaccines. The canine vaccines segment accounted for a slightly larger share (in terms of revenue) than the feline vaccines segment, due to higher average cost allied with canine vaccination. Similarly, the bovine vaccines sub-segment accounted for the largest share (in terms of revenue), followed by porcine.
Geographical Analysis and Regional Analysis:
Furthermore, based on geography the global market is analyzed under various regions namely, North America, Europe, Asia Pacific, Latin America and Middle-East & Africa. The European region is leading the veterinary vaccine market in terms of consumption, followed by the U.S. These two regions together account for more than 70% of the global veterinary vaccine market revenue.
Competitors Analysis of Veterinary Vaccines Market:
Some of the key players influencing the market are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health, Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health, Inc., Merck & Co. Inc, and Protein Sciences.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.1.1 Livestock vaccines
5.1.1.1 Bovine
5.1.1.2 porcine
5.1.1.3 Ovine
5.1.1.4 Poultry
5.1.1.5 Equine
5.1.2 Companion vaccines
5.1.2.1 canine
5.1.2.2 feline
5.2 Technology
5.2.1 Live attenuated vaccines
5.2.2 Inactivated vaccines
5.2.3 Recombinant vaccines
5.2.4 Toxoid vaccines
5.2.5 Subunit vaccines
5.2.6 DNA vaccines
5.2.7 Conjugate vaccines
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bayer Healthcare AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Bioniche Animal Health Canada
8.3 Sanofi Animal Health Inc.
8.4 Biogenesis Bago SA
8.5 Heska Corporation
8.6 Indian Immunologicals Ltd.
8.7 Boehringer Ingelheim GmbH
8.8 Novartis Animal Health, Inc.
8.9 Merck & Co. Inc.
8.10 Protein Sciences
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
